

VEGFA

Humanized Anti-VEGF-A (Bevacizumab) mAb

Catalog No.	CSB101A CSB101B	Quantity:	100 µg 1 mg
Alternate Names:	12-IgG1, F(ab)-12 IgG1, Fab-12 IgG1, rhuMAb-VEGF, Avastin		
Description:	<p>Bevacizumab, a humanized monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity and inhibits its interaction with VEGFR-1 and VEGFR-2. Bevacizumab is a functions as an angiogenesis inhibitor by inhibiting vascular endothelial growth factor A (VEGF-A), and slowing the growth of new blood vessels. Bevacizumab, sold under the brand name Avastin was approved for medical use in the United States in 2004 and approved by the European Medicines Agency (EMA) in January 2005 for use in colorectal cancer. It is a medication used to treat a number of types of cancers and specific eye disease such as age-related macular degeneration. It is given by injection into the eye (intravitreal).</p>		
Concentration:	1.0 mg/ml		
UniProt ID (target):	P15692		
Source:	CHO cell line		
Isotype:	Humanized IgG1 kappa		
Formulation:	PBS, pH 7.5		
Purity:	> 95% as determined by SDS-PAGE		
Biological Activity:	<p>EC₅₀ = 0.18 µg/ml, Bevacizumab binding VEGF by ELISA IC₅₀ = 0.047±0.0081 µg/ml, inhibits the VEGF-induced proliferation of HUVEC</p>		
Applications:	Functional studies, ELISA		
	Store at 2-8°C for up to 1 week, or undiluted in working aliquots at -20°C to -80°C for up to 1 year. Avoid freeze/thaw cycles.		

NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.



Cell Sciences®
 65 Parker Street
 Unit 11
 Newburyport, MA 01950

Toll Free: 888-769-1246
 Phone: 978-572-1070
 Fax: 978-992-0298

E-mail: info@cellsciences.com
 Website: www.cellsciences.com